VIRTACs - Protein Degradation as an Anti-Viral Strategy

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:1 publications

Grant number: EP/V008404/1

Grant search

Key facts

  • Disease

    COVID-19, Unspecified
  • Start & end year

    2021
    2024
  • Known Financial Commitments (USD)

    $568,439.62
  • Funder

    UK Research and Innovation (UKRI)
  • Principal Investigator

    David France
  • Research Location

    United Kingdom
  • Lead Research Institution

    University of Glasgow
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

As highlighted by the current Covid-19 pandemic, viruses are a constant threat to human health and prosperity. Viral infections kill millions of people every year and population growth, international travel and climate change mean that human populations are increasingly vulnerable to emerging viral threats. Further to the severe morbidity and mortality caused by viruses, lost productivity and livestock deaths mean viruses place a considerable burden on the global economy (estimated in the tens of billions of pounds worldwide each year). Developing new strategies to combat viral threats is of tremendous importance, as recognized by many organizations including the United Nations, World Health Organization, and UK Government. Most antiviral drugs work through a classical mechanism that involves a 1:1 interaction of the drug with its target. An emerging strategy in Medicinal Chemistry seeks to overcome this "occupancy based" limitation using a new mechanism called protein degradation. There are lots of potential advantages to the protein degradation approach, but its new enough that it hasn't really been explored much in an antiviral context. This project will explore the protein degradation mechanism in targeting 3 viruses of importance to human health: HIV, influenza, and the SARS-CoV-2 virus that is causing the current Covid-19 pandemic. Although we're not aiming to generate a new drug during this project period (that takes longer and costs more), we believe that this project will lay the groundwork for important new therapies in the future. There's no doubt that these therapies will be needed, as viruses are constantly developing resistance.

Publicationslinked via Europe PMC

Last Updated:38 minutes ago

View all publications at Europe PMC

Synthesis, Enantiomeric Resolution and Biological Evaluation of HIV Capsid Inhibition Activity for Racemic, (S)- and (R)-PF74.